Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Takeda Pharmaceutical Company Limited    4502   JP3463000004

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryAll NewsPress ReleasesOfficial PublicationsSector news

Takeda Pharmaceutical : Japan's Takeda to sell TachoSil surgical patch to Corza Health for 350 million euros

share with twitter share with LinkedIn share with facebook
09/16/2020 | 03:37am EDT
FILE PHOTO: Takeda Pharmaceutical's logo is seen at its headquarters in Tokyo

Takeda Pharmaceutical Co said on Wednesday it would sell its TachoSil surgical patch product to Corza Health for 350 million euros ($414.75 million) as the Japanese company continues to divest non-core businesses.

TachoSil, a surgical patch used for bleeding control

control, delivered $160 million in sales for Takeda in the fiscal year ended March 31, 2020, the company said in a release.

To reduce debt, Takeda has pledged to dispose of $10 billion worth of non-core assets.

Takeda is focusing on five key business areas: oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies.

($1 = 0.8439 euros)

(Reporting by Rocky Swift, editing by Louise Heavens)

share with twitter share with LinkedIn share with facebook
All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
09/25TAKEDA PHARMACEUTICAL : Announcement of decision on a basic plan for a merger wi..
AQ
09/24TAKEDA PHARMACEUTICAL : phRMA - Coming together to fight COVID-19, A conversatio..
AQ
09/24TAKEDA PHARMACEUTICAL : Announcement of decision on a basic plan for a merger (s..
PU
09/18FOUNDATION MEDICINE : and Takeda Announce Collaboration To Develop FoundationOne..
BU
09/18TAKEDA PHARMACEUTICAL : Presents New Data Highlighting Scientific Advancements i..
BU
09/17PODCAST : Women @ RopesTalk: Conversation With Chika Hirata, Takeda Japan
AQ
09/17TAKEDA PHARMACEUTICAL : to Divest TachoSil to Corza Health for EUR350 Million
AQ
09/17Takeda-led COVID-19 plasma product to begin trial this month
RE
09/16TAKEDA PHARMACEUTICAL : Opens New R&D Cell Therapy Manufacturing Facility to Sup..
AQ
09/16TAKEDA PHARMACEUTICAL : Japan's Takeda to sell TachoSil surgical patch to Corza ..
RE
More news
Financials
Sales 2021 3 267 B 30 943 M 30 943 M
Net income 2021 177 B 1 678 M 1 678 M
Net Debt 2021 3 935 B 37 266 M 37 266 M
P/E ratio 2021 46,7x
Yield 2021 4,59%
Capitalization 6 135 B 58 080 M 58 106 M
EV / Sales 2021 3,08x
EV / Sales 2022 2,81x
Nbr of Employees 47 495
Free-Float 99,0%
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Average target price 5 443,85 JPY
Last Close Price 3 925,00 JPY
Spread / Highest target 65,6%
Spread / Average Target 38,7%
Spread / Lowest Target 4,46%
EPS Revisions
Managers
NameTitle
Christophe Weber President, CEO & Representative Director
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Yasuhiko Yamanaka Director
Masato Iwasaki Director & President-Japan Pharma Business Unit
Sector and Competitors
1st jan.Capitalization (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED-9.40%58 080
JOHNSON & JOHNSON-0.14%383 497
ROCHE HOLDING AG5.40%304 339
MERCK & CO., INC.-8.82%209 750
PFIZER, INC.-8.73%200 326
NOVARTIS AG-12.61%190 402